News

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.
Novo Nordisk ( NVO 1.82%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...
The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.
Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...
Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.